Identification of plasma biomarkers for discrimination between tuberculosis infection/disease and pulmonary non tuberculosis disease

Marco Pio La Manna1,*, Valentina Orlando1, Paolo Li Donni2, Guido Sireci1,3, Paola Di Carlo4, Antonio Cascio4, Francesco Dieli1,3‡, Nadia Caccamo1,3‡

1 Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), Azienda Universitaria Ospedaliera Policlinico P. Giaccone, Palermo, Italy, 2 Dipartimento di Scienze Economiche, Aziendali e Statistiche, Università di Palermo, Palermo, Italy, 3 Dipartimento di Biopatologia e Biotecnologie Mediche, Università di Palermo, Palermo, Italy, 4 Department of Sciences for Health Promotion and Mother-Child Care “G. D’Alessandro”, University of Palermo, Palermo, Italy

☯ These authors contributed equally to this work.
‡ FD and NC are joint senior authors on this work.
* nadia.caccamo@unipa.it

Abstract

We used the Luminex Bead Array Multiplex Immunoassay to measure cytokines, chemokines and growth factors responses to the same antigens used for RD1-based Interferon γ Release Assay (IGRA) test. Seventy-nine individuals, 27 active TB, 32 latent infection subsets, 20 individuals derivative purified protein (PPD) negative (subjects that do not have any indurative cutaneous reaction after 72 hrs of intradermal injection of PPD) and with other pulmonary disease were retrospectively studied. Forty-eight analytes were evaluated by Luminex Assay in plasma obtained from whole blood stimulated cells. The diagnostic accuracies of the markers detected in the culture supernatants evaluated by ROC curve analysis revealed that 11 analytes (IL2, IP10, IFN-γ, IL13, MIG, SCF, b-NGF, IL12-p40, TRAIL, IL2Ra, MIF) discriminated between NON-TB and LTBI groups, with AUC for all analytes ≥0.73, while 14 analytes (IL2, IP10, IFN-γ, MIG, SCF, b-NGF, IL12-p40, TRAIL, IL2Ra, MIF, TNF-β, IL3, IFN-α2, LIF) discriminated between NON-TB and active TB groups, with AUC ≥0.78, that is a moderate, value in terms of accuracy of a diagnostic test. Finally, the combinations of seven biomarkers resulted in the accurate prediction of 88.89% of active TB patients, 82.35% of subjects with latent infection and 90% of non-TB patients, respectively. Taken together, our data suggest that combinations of whole blood
Mycobacterium tuberculosis (Mtbb) antigen dependent cytokines production could be useful as biomarkers to determine tuberculosis disease states when compared to non TB cohort.

Introduction
Tuberculosis (TB) continues to be the cause of death of 4000 people per day [1], and the World Health Organization (WHO) and all the people that are involved in the field are still searching solutions able to control and prevent the socio-economic and medical problems caused by this pathology. In 2014, the WHO approved a new strategy to reach the ambitious target of ending the global TB epidemic by 2035 [2, 3]: the End TB Strategy. The goal will be reached when TB related deaths and active TB disease incidence, compared to the data of 2015, will be reduced by 95% and 90%, respectively, with a decrease in incidence less than 10 per 100, 000 population [4, 5]. Therefore, the discovery, development, and rapid implementation of new diagnostic tools have been identified as important components of the End TB strategy of WHO [6, 7].

One of the limits of the available diagnostic tests is that it is not possible to discriminate infection from disease. Therefore, the search for simple and cheap diagnostic methods with the aim to discriminate patients with active disease from subjects with latent infection, with the objective to cure patients with active disease and to block the spread of the pathogen from subjects with latent infection that are at high risk to develop the disease and that can cause the transmission of infection to healthy subjects. The identification of biomarkers that are detectable using peripheral blood with simple technologies represents a crucial aspect in the field, due to the limit of the IGRA tests commercially available as diagnostic tests, that are not able to discriminate between infection and active disease. In order to bypass these limitations, new techniques, including transcript microarrays, flow cytometry of intracellular cytokines, and multiplex microbead-based immunoassay (Luminex assay) of cytokines, have recently been introduced [8–12]. Moreover, these cytokines/chemokines were analyzed as a single biomarker or in combination, in order to find a tool to discriminate, in an unequivocal way, subjects with latent infection from that with active disease. In these studies, some biomarkers were found at the high significant difference between patients with active disease and LTBI subjects; while in other studies other cytokines have been indicated in order to discriminate the infection from disease, demonstrating that several factors, other than the pathogen, could influence the cytokines/chemokines levels [13–15].

In the current study, on the basis of the WHO End TB strategy, we have evaluated the levels of different cytokines and chemokines from plasma samples obtained from unstimulated and antigen specific stimulated cells with the objective to discriminate active TB cases from latently infected contacts, or if the combination of different biomarkers could be useful as biosignature of disease/infection.

Materials and methods
Study participants
Seventy-nine individuals were retrospectively studied as here reported: (a) active TB group: 27 individuals diagnosed with TB (either with a positive culture for Mtb from sputum (48%) or with positive genexpert MTB/RIF, Mtb DNA resistance to rifampicin (52%) amplification results from biopsy specimens and/or biological fluids) 21 men, 6 women (age range 17–82 years) who started specific treatment within 8 days before enrolment; (b) latent infection
subsets (LTBI): 32 individuals (24 men, 8 women, age range 17–84 years) who reported household or equivalent close contact (work) with smear-positive pulmonary TB patients in the previous 3 months, tested PPD positive (when the diameter was major of 10 mm) second ATS guidelines and QuantiFERON Gold In-Tube (QFT IT), Qiagen, -positive(IFN-γ levels ≥ 0.35UI/ml), with negative chest radiographic results for pulmonary lesions and no prior preventive therapy; (c)other non-TB pulmonary infections (NON-TB): 20 individuals PPD negative (12 men, 8 women, age range 24–76 years); (d) healthy donors (HD): 20 individuals PPD negative (14 men, 6 women, age range 21–68 years).

Patients were recruited from the Department of Infectious Disease, University Hospital of Palermo. All patients were treated in accordance with Italian guidelines and received therapy for 6 months. Treatment was successful in all participants, all of whom completed the full course of anti-TB chemotherapy. None of the TB patients had evidence of HIV infection, or was being treated with steroid or other immunosuppressive or anti-tubercular drugs at the time of their first sampling. The study was approved by the Ethical Committee of the University Hospital in Palermo (approval number 13/2013), where the patients were recruited. Informed consent was signed by all participants. QFT, IT (Qiagen, Carnegie, VA, Australia).

Luminex multiplex Immunoassay Bio-Rad

The concentrations of 48 host cytokines and chemokines, including biomarkers that have been already validated, were investigated in samples from all the study participants. Experiments were performed in a blinded manner, according to the instructions of the kit manufacturers.

The principle of the technique is based on developing color coded microspheres by combining different ratios of two dyes and this combination can give up to 100 different combinations, which enables measurement of 100 different analytes. The technology combines ELISA and flow cytometry together where the capture antibody is conjugated with beads or microspheres whereas the secondary antibody is conjugated with fluorochrome which quantifies the antigen-antibody reaction by measuring the relative fluorescence intensity. The assays were performed according to the supplier’s instructions. Briefly, following pre wetting of plates, 50 μl precombined beads of all the 48 individual cytokines or chemokines were added and washed twice.

Plasma samples (25 μl) were diluted 1:2 with the kit serum matrix and added to the plate. The plate was shaken for 30 s at 1000 RPM and then incubated for 1 h on plate shaken at 300 RPM at room temperature. The plates were washed twice and 25 μl of detection antibody was added per well and incubated for one hour on a plate shaker. Then strepatavidin-PE conjugate (50μl per well) was added and incubated for 30 min at room temperature. Finally, the plate was washed three times and 150 μl of sheath fluid was added to each well and then the plate was read on the Bio-Plex platform (Bio-Rad), with the Bio-Plex Software version 6.1 used for bead acquisition and analysis.

QuantiFERON TB-gold in tube (QFT-IT)

QFT-IT (Cellestis Limited, Carnegie, Victoria, Australia) was performed using TB antigen-, mitogen- and unstimulated tube (nil). The tube containing TB antigen uses overlapping
peptides from CFP-10 and ESAT-6 and TB7.7. QFT is a test for cell-mediated immune (CMI) responses to peptide antigens that simulate mycobacterial proteins. These proteins, ESAT-6, CFP-10, and TB7.7 (p4), are absent from all BCG strains and from most non tuberculous mycobacteria with the exception of M. kansasii, M. szulgai, and M. marinum. The assay was performed and the results were scored as indicated by the manufacturer’s instructions (the cut-off value for a positive test was 0.35 IU/ml). An indeterminate score was assigned if the IFN-γ response to the mitogen after subtracting the nil IFN-γ response was <0.5 IU/ml or if the nil IFN-γ response was >8 IU/ml.

**Statistical analysis**

Differences in the concentrations of host biomarkers detected in plasma samples from TB patients, LTBI subjects, NON-TB and HD were evaluated using the Kruskal-Wallis test distributed data. Biomarkers were compared between multiple groups using Kruskal Wallis tests. A non-parametric test able to compare more than two experimental groups. Dunn’s multiple comparison tests was used for post hoc correction to account for multiple comparisons.

Test performance in terms of sensitivity (ability of the test to identify the real positive subjects) and specificity (ability of the test to identify the real negative subjects) was evaluated for each cytokine by a ROC (Receiving Operating Characteristic) curve, the selective validation method of a quantitative diagnostic test in a population. The proportion of patients correctly diagnosed, that is the test accuracy, is proportional to the area under the curve (AUC), which can assume values between 0.5 (50% accuracy) and not accurate for AUC = 0.5, the test is poorly accurate for 0.5 < AUC ≤ 0.7, the test is moderately accurate for 0.7 < AUC ≤ 0.9, the test is highly accurate for 0.9 < AUC < 1 and the test is perfect for AUC = 1. The ROC curve also allows to identify the best cut off value that maximizes the difference between true positive subjects and false positives ones [16]. P-values <0.05were considered significant. The likelihood ratios was used for assessing the value of performing a diagnostic test.

General discriminant analysis (GDA) was used to evaluate the abilities of combinations of biomarkers to discriminate between Mtb-infected and uninfected groups or between active TB and LTBI. Optimal combinations of biomarkers were investigated by performing a best subsets analysis. All statistical analyses were performed and graphics were prepared using Statistica version 13 software (Statsoft, Ohio, USA), and GraphPad Prism software version 5.

**Results**

**Measurement of host markers in LTBI subjects, TB patients and patients with other pulmonary infections**

The baseline concentrations of host markers in TB patients were compared to the levels detected in subjects with LTBI and patients with pulmonary infections other than TB in order to avoid any unspecific background levels independently on mycobacterial stimulation. Initially, we scored those cytokine levels which were over the normal range concentrations, as calculated by the manufacturer in n = 66 healthy individuals. For comparison, we measured the 48 analytes in the serum of an independent cohort of n = 20 age- and sex-matched healthy individuals and found that reference values from the manufacturer were fully consistent with those from our independent cohort of healthy subjects (Wilcoxon p value = 0.26 for comparison of the two series of data). (Table 1).

The concentrations of 30 out of the 48 tested analytes were over the normal range in LTBI subjects and patients with active TB disease (Table 2). Baseline serum levels of 28 cytokines were found elevated in both groups, with percentages ranging from 40 to 100% in LTBI
| Analyte      | pg/ml (Range) | pg/ml (Observed) | pg/ml (Median) | pg/ml (Mean) |
|-------------|--------------|------------------|----------------|-------------|
| IL-1α       | 0.50–1.40    | 0.40–1.40        | 0              | 0.12        |
| IL-1β       | <0.70        | 0.02–0.70        | 0              | 0.01        |
| IL-1ra      | 6–665        | 0.20–665         | 23.94          | 42.01       |
| IL-2        | 2–90         | 0.03–90          | 1.24           | 6.46        |
| IL-2Ra      | 28–594       | 28–594           | 102.66         | 116.85      |
| IL-3        | 13–170       | 13–170           | 41.06          | 44.54       |
| IL-4        | 0.06–3       | 0.01–3           | 0              | 0.10        |
| IL-5        | 1–7          | 0.01–7           | 0              | 0.15        |
| IL-6        | 0.50–9       | 0.02–9           | 0              | 0.73        |
| IL-7        | 0.60–13      | 0.01–14          | 0              | 0.27        |
| IL-8        | 0.40–116     | 0.08–116         | 0              | 7.21        |
| IL-9        | 2–500        | 0.38–500         | 19.40          | 37.50       |
| IL-10       | 0.40–2       | 0.10–2           | 0              | 0.13        |
| IL-12(p40)  | 36–646       | 36–646           | 60.19          |             |
| IL-12(p70)  | 3–6          | 0.10–6           | 0              | 0.14        |
| IL-13       | 0.80–9       | 0.01–9           | 0              | 0.33        |
| IL-15       | 2–5          | 0.06–5           | 0              | 0.31        |
| IL-16       | 10–1,270     | 10–1,270         | 77.50          | 94.79       |
| IL-17       | 2–31         | 0.22–31          | 0              | 2.30        |
| IL-18       | 9–812        | 9–812            | 68.05          | 75.71       |
| IFN-α2      | 14–79        | 3.30–63          | 0              | 16.07       |
| IFN-γ       | 7–124        | 0.60–124         | 8.68           | 13.43       |
| TNF-α       | 6–98         | 0.10–98          | 0              | 5.92        |
| TNF-β       | 1–13         | 0.71–13          | 0              | 0.31        |
| TRAIL       | 8–272        | 8–272            | 66.61          | 65.91       |
| CXCL1 (GRO-α)| 9–365       | 9–365            | 22.35          | 36.33       |
| CXCL9 (MIG) | 86–7,911     | 86–7,911         | 289            | 617.05      |
| CXCL10 (IP-10)| 6–637   | 5.90–637         | 32.24          | 93.61       |
| CXCL12 (SDF-1α)| 8–92     | 8–92             | 0              | 13.79       |
| CCL2 (MCP-1)| 2–48         | 2–48             | 17.95          | 18.24       |
| CCL3 (MIP-1α)| <2          | 0.01–2           | 0              | 0.15        |
| CCL4 (MIP-1β)| 5–47       | 1.70–47          | 11.24          | 14.75       |
| CCL5 (RANTES)| 100–2,282  | 100–2,282        | 0              | 203.64      |
| CCL7 (MCP-3)| 1–78         | 1–78             | 2.25           | 3.28        |
| CCL11 (Eotaxin)| 2–39   | 1.20–39          | 0              | 3.80        |
| CCL27 (CTACK)| 1–1,086    | 1–1,086          | 196            | 246.51      |
| G-CSF       | <1.50        | <1.50            | 0              | 0.02        |
| M-CSF       | 6–208        | 6–208            | 29.64          | 48.68       |
| GM-CSF      | 3–122        | 0.80–122         | 6.78           | 12.47       |
| SCF         | 16–837       | 16–837           | 167.57         | 172.88      |
| SGCF-β      | 6,05–130,932 | 6,05–130,932    | 47,870         | 48,312      |
| LIF         | 4–55         | 4–55             | 14.85          | 17.20       |
| MIF         | 6–2,003      | 6–2,003          | 72.40          | 170.29      |
| FGF-β       | 4–55         | 1.30–55          | 7.54           | 9           |
| b-NGF       | <1.10        | <1.10            | 0              | 0.04        |
| PDGF-BB     | 6–3,667      | 6–3,667          | 180.10         | 394.87      |
| VEGF        | 0.50–9       | 0.01–9           | 0              | 0.43        |
| HGF         | 63–1,868     | 63–1,868         | 195.20         | 255.24      |

https://doi.org/10.1371/journal.pone.0192664.t001
subjects and from 44 to 100% in TB patients. Baseline levels of no single analyte were differentially increased in sera from LTBI subjects. Conversely, baseline level of IFNα2 was slightly increased over the maximum normal range value (1.14-fold) in patients with active TB, but this was only detected in approximately one third of the patients, while the baseline of GM-CSF was increased in LTBI compared to active TB (1.20-fold) in the 50% of LTBI subjects.

To understand whether increased levels of several different analytes were a feature of TB infection/disease or were found also in other pathologic conditions, we measured their baseline concentrations in sera from patients with other non-TB pulmonary infections (n.20). As reported in Table 2, 29 out of 30 analytes were increased both in sera of TB patients and in NON-TB patients over the normal range, suggesting that elevated baseline levels of these molecules reflect an active infection/inflammation state, irrespective of the etiology.

To check for potential biomarkers capable of differentiating between LTBI subjects and patients with active TB, and between these latter and patients with other non-TB pulmonary infections, we compared the median baseline analyte concentrations in the tested LTBI, TB and NON-TB groups by Kruskal-Wallis tests. Results show (Table 2) that median baseline levels of 7 analytes, namely IL-1β, IL2, IL-8, IL-12p70, MCP-1, PDGF-BB, VEGF and LIF were significantly different among LTBI subjects, TB and NON-TB patients; furthermore, after post-test correction using Dunn’s multiple comparison tests, the median concentrations of IL-1β, IL12p70 and VEGF were significantly higher in LTBI subjects compared to NON-TB patients, and the median concentrations of PDGF-BB, IL-1β, IL-2, IL-8, IL12p70, MCP-1 and LIF were significantly higher in TB patients compared to NON-TB patients (Fig 1).

Of note, however, median baseline concentrations of the 48 tested analytes did not significantly differ between LTBI subjects and patients with active TB, indicating that there was no baseline biomarkers capable to discriminate between LTBI and active TB disease.

When the diagnostic accuracies of individual host markers were investigated by ROC curve analysis, the area under the ROC curve (AUC) was ≥ 0.70 for the 8 markers found significantly increased in LTBI subjects and active TB patients (Table 3). These markers have proven to be very effective in distinguishing non TB from active TB. At their optimal unstimulated cut off values, IL-8, IL-12p70 and MCP-1 had a sensitivity of 72%, 76% and 73% respectively, and IL-1β, PDGF-BB and LIF had a specificity of 85%, 90% and 80% respectively. The best performance characteristic was with unstimulated IL12p70 with a sensitivity of 73% and specificity of 78% (Table 3). Representative plots showing the 10 individual baseline host markers with the best diagnostic accuracy are shown in Fig 2.

Measurement of mycobacterial antigen-specific host markers in LTBI subjects, TB patients and patients with other pulmonary infections

We compared the median analyte concentrations in the supernatants of mycobacterial Ag stimulated cells from LTBI, TB and NON-TB groups by Kruskal-Wallis tests. In order to exclude the contribution of unstimulated marker level to the diagnosis of TB infection/disease, for each study participant before the analysis of the data, the antigen specific responses of the different cytokines and chemokines were evaluated by subtraction of the unstimulated levels from the antigen-stimulated response.

Results show (Table 4) that in response to Mtb antigen specific stimulation by ESAT-6/CFP-10, median concentrations of 14 analytes, namely IL-2, IP-10, IFN-γ, MIG, SCF, b-NGF, IL-12-p40, MIF, TRAIL, IL-2ra, TNF-β, IL-3, IFNα2, LIF and IL-13 were significantly different in the active TB and LTBI groups, compared to NON-TB patients. Furthermore, after post-test correction using Dunn’s multiple comparison tests, the median concentrations of IL12-p40,
Table 2. Medians and statistical analysis of the cytokines baseline levels.

| Analyte | Non TB | LTBI | Active TB | Normal range | Kruskal-Wallis test | Dunn’s multiple comparisons test |
|---------|-------|------|-----------|---------------|---------------------|---------------------------------|
|         | % of patients upper normal range | % of patients upper normal range | % of patients upper normal range | p value | NIL NEG vs. NIL LTBI | p value | NIL NEG vs. NIL ACTIVE TB | p value | NIL LTBI vs. NIL ACTIVE TB | p value |
| Basic FGF | 90% | 78% | 96% | 1.30–55.00 | 0.0528 | ns >0.9999 | 0.1022 | 0.1197 |
| Eotaxin | 85% | 88% | 93% | 1.20–39.00 | 0.5465 | ns >0.9999 | 0.9999 | 0.851 |
| G-CSF | 100% | 97% | 100% | <1.50 | 0.1157 | ns 0.7201 | 0.1141 | 0.8368 |
| GM-CSF | 45% | 50% | 48% | 0.80–122.00 | 0.8664 | ns >0.9999 | 0.9999 | 0.9999 |
| IFN-γ | 40% | 75% | 70% | 0.60–124.00 | 0.0537 | ns 0.0519 | 0.2127 | 0.9999 |
| IL-1β | 100% | 97% | 100% | 0.02–0.70 | 0.0051 | ** 0.0179 | 0.0077 | >0.9999 |
| IL-1α | 20% | 16% | 15% | 0.20–665.00 | 0.0562 | ns 0.1565 | 0.0629 | >0.9999 |
| IL-2 | 10% | 6% | 4% | 0.03–90.00 | 0.0341 | * 0.1194 | 0.036 | >0.9999 |
| IL-4 | 85% | 84% | 93% | 0.01–3.00 | 0.218 | ns 0.253 | 0.6588 | >0.9999 |
| IL-5 | 5% | 6% | 0% | 0.01–7.00 | 0.7723 | ns >0.9999 | 0.9999 | >0.9999 |
| IL-6 | 100% | 97% | 100% | 0.02–9.00 | 0.0934 | ns 0.0917 | 0.4415 | >0.9999 |
| IL-7 | 30% | 38% | 26% | 0.01–14.00 | 0.4545 | ns 0.629 | >0.9999 | >0.9999 |
| IL-8 | 100% | 97% | 93% | 0.08–116.00 | 0.0161 | * 0.5306 | 0.0132 | 0.2461 |
| IL-9 | 20% | 6% | 22% | 0.38–500.00 | 0.1278 | ns 0.6297 | 0.1279 | >0.9999 |
| IL-10 | 100% | 97% | 100% | 0.10–2.00 | 0.7698 | ns >0.9999 | 0.9999 | >0.9999 |
| IL-12(p70) | 100% | 91% | 96% | 0.10–6.00 | 0.0062 | ** 0.0167 | 0.01 | >0.9999 |
| IL-13 | 20% | 28% | 35% | 0.01–9.00 | 0.0867 | ns 0.2386 | 0.0994 | >0.9999 |
| IL-15 | 55% | 69% | 56% | 0.06–5.00 | 0.2735 | ns 0.3651 | >0.9999 | 0.8823 |
| IL-17 | 95% | 100% | 100% | 0.22–31.00 | 0.0779 | ns >0.9999 | 0.0819 | 0.4117 |
| IP-10 | 80% | 81% | 89% | 5.90–637.00 | 0.2025 | ns 0.6522 | >0.9999 | 0.277 |
| MCP-1 (MCAF) | 95% | 97% | 100% | 2.00–48.00 | 0.0102 | * 0.1554 | 0.0075 | 0.5804 |
| MIP-1α | 95% | 97% | 96% | 0.01–2.00 | 0.1592 | ns 0.2462 | 0.2905 | >0.9999 |
| MIP-1β | 85% | 69% | 85% | 1.70–47.00 | 0.4969 | ns 0.7958 | >0.9999 | >0.9999 |
| PDGF–BB | 0% | 0% | 7% | 6.00–3,667.00 | 0.0143 | * 0.5805 | 0.0123 | 0.201 |
| RANTES | 85% | 84% | 81% | 100.00– | 0.3143 | ns 0.7307 | 0.4309 | >0.9999 |
| TNF-α | 55% | 81% | 89% | 0.10–98.00 | 0.051 | ns 0.0652 | 0.1298 | >0.9999 |
| VEGF | 100% | 100% | 100% | 0.01–9.00 | 0.0298 | * 0.039 | 0.0814 | >0.9999 |
| CTACK | 60% | 76% | 100% | 1.00–1,086.00 | 0.3238 | ns 0.5438 | 0.5198 | >0.9999 |
| GRO-α | 80% | 94% | 100% | 9.00–365.00 | 0.6316 | ns >0.9999 | 0.9999 | >0.9999 |
| HGF | 30% | 24% | 11% | 63.00–1,868.00 | 0.5387 | ns >0.9999 | 0.8739 | >0.9999 |
| IFN-α2 | 60% | 59% | 44% | 3.30–63.00 | 0.6583 | ns >0.9999 | 0.9999 | >0.9999 |
| IL-1α | 59% | 100% | 100% | 0.40–1.40 | 0.4344 | ns >0.9999 | 0.8889 | 0.7695 |
| IL-2Ra | 20% | 12% | 11% | 28.00–594.00 | 0.7087 | ns >0.9999 | 0.9999 | >0.9999 |
| IL-3 | 100% | 94% | 100% | 13.00–170.00 | 0.8275 | ns >0.9999 | 0.9999 | >0.9999 |
| IL-12(p40) | 80% | 71% | 89% | 36.00–646.00 | 0.5405 | ns >0.9999 | 0.9999 | 0.8275 |
| IL-16 | 0% | 0% | 0% | 10.00–1,270.00 | 0.131 | ns 0.1413 | 0.377 | >0.9999 |
| IL-18 | 10% | 6% | 6% | 9.00–812.00 | 0.2328 | ns 0.2645 | 0.7535 | >0.9999 |
| LIF | 80% | 82% | 94% | 4.00–55.00 | 0.048 | * >0.9999 | 0.0751 | 0.1916 |
| MCP-3 | 70% | 82% | 94% | 1.00–78.00 | 0.2451 | ns >0.9999 | 0.3016 | 0.9322 |
| M-CSF | 40% | 53% | 28% | 6.00–208.00 | 0.6022 | ns >0.9999 | 0.9999 | 0.9684 |
| MIF | 80% | 65% | 94% | 6.00–2,003.00 | 0.263 | ns >0.9999 | 0.3635 | 0.7695 |

(Continued)
IL-2ra, SCF, TRAIL, IL-2, IFN-γ, IP-10, b-NGF, LIF and MIG were significantly higher in the active TB and LTBI subjects compared to NON-TB patients, and the median concentrations of IFN-α2, IL-3, and TNF-β were significantly higher in TB patients compared to NON-TB patients (Fig 3). Finally, the median concentrations of IL-13 was significantly higher only in LTBI compared to NON-TB patients. As with baseline levels of tested analytes, there were no statistically significant differences in median concentrations of the tested analytes in Mtb antigen-stimulated samples from LTBI subjects and patients with active TB, except for MIF that shows an appreciable and statistically significant decrease in the active TB group compared to LTBI and non TB groups.

The biomarkers detected were analysed using receiver operating characteristic (ROC) curves, the test accuracy that is proportional to the area under the curve (AUC), which can assume values between 0.5 (50% accuracy) and 1 (100% accuracy). The ROC curve also allows to identify the best cut off value that maximizes the difference between true positive subjects and false positives ones. ESAT-6/CFP-10-specific levels of 11 analytes (IL2, MIG, SCF, TRAIL, b-NGF, IL12-p40, IL2Ra, IL13, IFN-γ, IP10 and LIF) discriminated between NON-TB and LTBI groups, with AUC >0.73. Out of these 8 markers, ESAT-6/CFP-10-specific level of MIG and SCF had the best sensitivity and specificity of >90% (Table 5 and Fig 4).

Similarly, when the diagnostic accuracies of the markers detected in the culture supernatants were evaluated by ROC curve analysis, ESAT-6/CFP-10-specific levels of 14 analytes (IL2, SCF, TRAIL, MIG, IL12-p40, b-NGF, MIF, TNF-β, IFN-α2, IFN-γ, IL3, IP10, LIF, IL2 Ra,) discriminated between NON-TB and active TB groups, with AUC >0.78. Two out of these 14 markers, ESAT-6/CFP-10-specific level of MIG and SCF had again the best sensitivity and specificity of >90% (Table 6 and Fig 5).

**General discriminant analysis (GDA)**

To determine whether combinations of multiple biomarkers could improve the ability to detect Mtb-infected individuals, we examined the performance of all combinations of 23 analytes.
Fig 1. Scatter plots showing biomarker concentrations in unstimulated supernatants from participants with non TB disease (triangles), LTBI (squares), active TB patients (circle). Biomarkers were measured by Luminex assay. Median concentrations are indicated with horizontal bars. Statistical differences were analyzed using Kruskal-Wallis test with Dunn’s correction. *p<0.05, **p<0.01.
https://doi.org/10.1371/journal.pone.0192664.g001
biomarker responses (PDGF-NIL, IL1β NIL, IL2 NIL, IL8 NIL, IL12p70 NIL, MCP-1 NIL, VEGF NIL, LIF NIL, IL2 Ag-NIL, IP10 Ag-NIL, IFN-γ Ag-NIL, MIF Ag-NIL, SCF Ag-NIL, bNGF Ag-NIL, IL12-p40, MIF Ag-NIL, TRAIL Ag-NIL, IL2RaAg-NIL, IL13 Ag-NIL, TNF-β Ag-NIL, IL3 Ag-NIL, IFN-α2 Ag-NIL, LIF Ag-NIL) significantly differed between Mtb-infected cases (active TB n. 27, LTBI n. 32) and non TB group n. 20 (see also Figs 2 and 3).

Using a GDA, all of the top–six or seven biomarker combinations (Table 7) accurately predicted active TB patients, LTBI subjects and non TB patients. In particular, seven biomarker combinations could predicted from 77.78 to 88.89% of active-TB patients, from 64.71 to 82.35% of LTBI subjects and from 90% to 100% of non TB patients. IL-2 was the biomarker most frequently included in the top seven-biomarker models, followed, in order, by IFN-γ, MIF, IL2Ra, LIF[Nil], followed by PDGF-BB[Nil], TRAIL and MCP-1[Nil] (Table 7).

The top six biomarker combinations could predicted from 77.78% to 88.89% of active TB patients, from 64,71 to 70,59% of LTBI subjects and from 80% to 100% of non TB patients.

Table 3. ROC curves features of markers increased in LTBI and Active TB.

| Marker       | Area under the ROC curve | Std. Error | 95% confidence interval | Pvalue | cutoff | Sensitivity % | Specificity % | 95% CI | 95% CI | Likelihood ratio |
|--------------|--------------------------|------------|-------------------------|--------|--------|---------------|---------------|-------|-------|-----------------|
| IL-1β        | 0.7283                   | 0.0734     | 0.5844 to 0.8722        | 0.00669| > 373.1| 63.33         | 34.86% to 80.07% | 85    | 62.11% to 96.79%| 4.222 |
| IL12 p70     | 0.7257                   | 0.07212    | 0.5843 to 0.8671        | 0.00862| > 72.69| 53.13         | 53.47% to 70.91% | 83.33 | 58.58% to 96.42%| 3.188 |
| IL-2         | 0.6713                   | 0.08274    | 0.5091 to 0.8335        | 0.04891| > 17.20| 63.33         | 43.86% to 80.07% | 72.22 | 46.32% to 90.31%| 2.28  |
| IL-8         | 0.6161                   | 0.08502    | 0.4495 to 0.7828        | 0.1649 | > 10992| 67.74         | 48.63% to 83.32% | 60    | 36.05% to 80.88%| 1.694 |
| MCP-1        | 0.6613                   | 0.07746    | 0.5094 to 0.8132        | 0.05765| > 1092 | 54.84         | 36.03% to 72.68% | 73.68 | 48.80% to 90.85%| 2.084 |
| PDGF-BB      | 0.6094                   | 0.08119    | 0.4502 to 0.7685        | 0.188  | > 1230 | 53.13         | 34.74% to 70.91% | 55    | 31.53% to 76.94%| 1.181 |
| VEGF         | 0.6938                   | 0.07373    | 0.5492 to 0.8383        | 0.01972| > 260.9| 50            | 31.89% to 68.11% | 90    | 68.30% to 98.77%| 5     |
| LIF          | 0.5875                   | 0.1156     | 0.3609 to 0.8141        | 0.4606 | > 112.3| 62.5          | 35.43% to 84.80% | 70    | 34.75% to 93.33%| 2.083 |

**Table 3. ROC curves features of markers increased in LTBI and Active TB.**

**ROC curve of non TB vs LTBI**

| Marker       | Area under the ROC curve | Std. Error | 95% confidence interval | Pvalue | cutoff | Sensitivity % | Specificity % | 95% CI | 95% CI | Likelihood ratio |
|--------------|--------------------------|------------|-------------------------|--------|--------|---------------|---------------|-------|-------|-----------------|
| IL-1β        | 0.7611                   | 0.07001    | 0.6239 to 0.8984        | 0.00242| > 355.7| 55.56         | 35.33% to 74.52% | 85    | 62.11% to 96.79%| 3.704 |
| IL12 p70     | 0.7789                   | 0.0725     | 0.6368 to 0.9210        | 0.00201| > 57.60| 72            | 50.61% to 87.93% | 77.78 | 52.36% to 93.59%| 3.24  |
| IL-2         | 0.7318                   | 0.07671    | 0.5814 to 0.8822        | 0.00927| > 19.65| 57.69         | 36.92% to 76.65% | 77.78 | 52.36% to 93.59%| 2.596 |
| IL-8         | 0.744                    | 0.08302    | 0.5812 to 0.9068        | 0.00534| > 14618| 76            | 54.87% to 90.64% | 70    | 45.72% to 88.11%| 2.533 |
| MCP-1        | 0.7692                   | 0.07132    | 0.6294 to 0.9091        | 0.00225| > 1118 | 73.08         | 52.21% to 88.43% | 73.68 | 48.80% to 90.85%| 2.777 |
| PDGF-BB      | 0.7462                   | 0.07233    | 0.6044 to 0.8879        | 0.00458| > 1821 | 57.69         | 36.92% to 76.65% | 90    | 68.30% to 98.77%| 5.769 |
| VEGF         | 0.7058                   | 0.07795    | 0.5530 to 0.8586        | 0.01778| > 161.3| 61.54         | 40.57% to 79.77% | 70    | 45.72% to 88.11%| 2.051 |
| LIF          | 0.7444                   | 0.1007     | 0.5469 to 0.9419        | 0.03494| > 155.7| 61.11         | 35.75% to 82.70% | 80    | 44.59% to 97.48%| 3.056 |

https://doi.org/10.1371/journal.pone.0192664.t003
Fig 2. Receiver operating characteristic (ROC) curves for the baseline cytokine values comparing LTBI subjects and patients with active TB with non TB patients. The solid line shows the result of absolute values of each biomarker. The area under the curve (AUC) is indicated.

https://doi.org/10.1371/journal.pone.0192664.g002
Table 4. Medians and statistical analysis of cytokine levels after antigen specific stimulation with subtraction of baseline.

| Analyte | % of patients upper normal range | % of patients upper normal range | % of patients upper normal range | pg/ml | p value | Dunn’s multiple comparisons test |
|---------|---------------------------------|---------------------------------|---------------------------------|-------|---------|-------------------------------|
|         | Non TB                          | LTBI                            | Active TB                        |       |         |                               |
| Basic FGF | 0%                              | 0%                              | 0%                              |       |         |                               |
| Eotaxin  | 0%                              | 12%                             | 4%                              | 1.30–55.0 | 0.3507 | ns                             |
| G-CSF    | 50%                             | 38%                             | 36%                              | <1.50 | 0.268   | ns                             |
| GM-CSF   | 0%                              | 4%                              | 0%                              | 0.80–122.00 | 0.8174 | ns                             |
| IFN-γ    | 10%                             | 42%                             | 48%                              | 0.60–124.00 | 0.003  | 0.0004                        |
| IL-1β    | 45%                             | 42%                             | 64%                              | 0.02–0.70 | 0.3585 | 0.5116                        |
| IL-1α    | 0%                              | 16%                             | 4%                              | 0.20–665.00 | 0.2291 | <0.0001                       |
| IL-2     | 0%                              | 69%                             | 68%                              | 0.03–90.00 | <0.0001 | 0.0001                        |
| IL-4     | 5%                              | 15%                             | 8%                              | 0.01–3.00  | 0.311  | ns                             |
| IL-5     | 0%                              | 8%                              | 4%                              | 0.01–7.00  | 0.0339 | 0.8795                        |
| IL-6     | 70%                             | 46%                             | 44%                              | 0.02–9.00  | 0.6    | ns                             |
| IL-7     | 15%                             | 15%                             | 12%                              | 0.01–14.00 | 0.6539 | ns                             |
| IL-8     | 45%                             | 42%                             | 36%                              | 0.08–116.00 | 0.3979 | ns                             |
| IL-9     | 0%                              | 0%                              | 0%                              | 0.38–500.00 | 0.6374 | ns                             |
| IL-10    | 30%                             | 15%                             | 20%                              | 0.10–2.00  | 0.0397 | 0.035                         |
| IL-12(p70) | 15%                            | 15%                             | 16%                              | 0.10–6.00  | 0.0421 | 0.0672                        |
| IL-13    | 0%                              | 23%                             | 28%                              | 0.01–9.00  | 0.0033 | ** 0.0022                     |
| IL-15    | 25%                             | 42%                             | 36%                              | 0.06–5.00  | 0.6884 | ns                             |
| IL-17    | 25%                             | 42%                             | 36%                              | 0.22–31.00 | 0.7224 | ns                             |
| IP-10    | 45%                             | 69%                             | 84%                              | 5.90–637.00 | 0.0026 | 0.0048                        |
| MCP-1 (MCAF) | 45%                           | 81%                             | 68%                              | 2.00–48.00 | 0.4415 | 0.6271                        |
| MIP-1a    | 40%                             | 38%                             | 32%                              | 0.01–2.00  | 0.3835 | ns                             |
| MIP-1b    | 50%                             | 31%                             | 60%                              | 1.70–47.00 | 0.0835 | ns                             |
| PDGF-BB  | 0%                              | 0%                              | 0%                              | 6.00–3,667.00 | 0.0423 | 0.1245                       |
| RANTES    | 20%                             | 23%                             | 24%                              | 100.00–2,282.00 | 0.7542 | ns                             |
| TNF-α     | 20%                             | 35%                             | 28%                              | 0.10–98.00 | 0.79  | ns                             |
| VEGF      | 15%                             | 8%                              | 4%                              | 0.01–9.00  | 0.0015 | ** 0.0034                     |
| CTACK     | 0%                              | 0%                              | 0%                              | 1.00–1,086.00 | 0.5625 | 0.9307                        |
| GRO-α     | 40%                             | 59%                             | 44%                              | 9.00–365.00 | 0.7153 | ns                             |
| HGF       | 0%                              | 0%                              | 0%                              | 63.00–1,868.00 | 0.1554 | 0.1701                        |
| IFN-α2    | 0%                              | 12%                             | 17%                              | 3.30–63.00  | 0.0333 | 0.1087                        |
| IL-1a     | 30%                             | 47%                             | 33%                              | 0.40–14.00 | 0.6236 | ns                             |
| IL-2Ra    | 0%                              | 0%                              | 0%                              | 28.00–594.00 | 0.0195 | 0.0401                        |
| IL-3      | 0%                              | 47%                             | 67%                              | 13.00–170.00 | 0.0419 | 0.1203                       |
| IL-12(p40) | 0%                            | 24%                             | 22%                              | 36.00–646.00 | 0.0037 | 0.0133                        |
| IL-16     | 0%                              | 0%                              | 0%                              | 10.00–1,270.00 | 0.3716 | 0.6493                        |
| IL-18     | 0%                              | 0%                              | 0%                              | 9.00–812.00 | 0.3452 | 0.5321                        |
| LIF       | 0%                              | 59%                             | 50%                              | 4.00–55.00  | 0.0346 | 0.0629                        |
| MCP-3     | 20%                             | 53%                             | 50%                              | 1.00–78.00  | 0.1776 | 0.1908                        |
| M-CSF     | 0%                              | 6%                              | 0%                              | 6.00–208.00 | 0.3932 | 0.8376                        |
| MIF       | 40%                             | 47%                             | 17%                              | 6.00–2,003.00 | 0.0029 | 0.0029                        |
| MIG       | 0%                              | 53%                             | 72%                              | 86.00–7,911.00 | 0.0008 | 0.0004                        |
| b-NGF     | 20%                             | 71%                             | 89%                              | <1.10     | 0.0044 | 0.0102                        |
| SCF       | 0%                              | 0%                              | 0%                              | 16.00–837.00 | 0.0004 | 0.0051                        |
| SCGF-b    | 10%                             | 6%                              | 0%                              | 6.054.00–13,093.00 | 0.3387 | ns                             |
| SDF-1a    | 20%                             | 41%                             | 39%                              | 8.00–92.00  | 0.2878 | 0.068                          |
| TNF-β     | 0%                              | 41%                             | 50%                              | 0.71–13.00  | 0.0098 | 0.0832                        |

(Continued)
IL2, IFN-γ, LIF, MIF were frequently occurring biomarkers, followed by MCP-1[Nil], IL12-p40 and TRAIL. These results, clearly demonstrate that Mtb infection display a different combination of cytokines/chemokines expression, highlighting that the immune response is completely different between infection and non TB status.

Table 4. (Continued)

| Analyte | % of patients upper normal range | % of patients upper normal range | pg/ml | p value | p value | p value | p value |
|---------|---------------------------------|---------------------------------|-------|---------|---------|---------|---------|
| TRAIL   | 0%                              | 6%                              | 17%   | 8.00–272.00 | 0.0013 | 0.0092 | 0.013   | > 0.9999 |

Bold cytokines show appreciable and statistically significant differences between non-TB and LTBI or active TB

*p<0.05
**p<0.01
***p<0.001.

https://doi.org/10.1371/journal.pone.0192664.t004

Fig 3. Scatter plots showing biomarker concentrations in antigen stimulated supernatants with subtracted Nil value from participants with non TB disease (triangles), LTBI (squares), active TB patients (circle). Biomarkers were measured by Luminex assay. Median concentrations are indicated with horizontal bars. Statistical differences were analyzed using Kruskall Wallis tests. *p<0.05, **p<0.01.

https://doi.org/10.1371/journal.pone.0192664.g003
Discussion

In the present study, we have investigated the potential role of 48 cytokines/chemokines in plasma obtained from stimulated whole blood of adults, as biomarkers of infection/disease by comparing patients with active TB disease with LTBI subjects and with non-TB patients. We have shown that multiple biomarkers detected in the antigen stimulated supernatants can contribute to a diagnostic signature with the ability to discriminate between mycobacterial infected patients and non TB patients.

Several groups of research have focused their studies on assessing the quality of several biomarkers, that could have poor specificity and sensitivity when used alone, but which show a good performance when used in combination.

Preliminary data on the studies of biomarkers available in internet web such as PubMed, Embase, and Web of Science have reported either diagnostic accuracy and statistical significance of TB biomarkers able to identify active TB even if lacking of validation; in particular, for the majority of biomarkers (n = 399), diagnostic performance is not reported (161 biomarkers), or is based on testing of a non-blinded, usually retrospective set of conveniently obtained samples (170 biomarkers), or on blinded testing in a single study (68 biomarkers) as recently reported by Yerlikaya et al.[17].

From these studies, only 12 biomarkers have been confirmed in studies where these biomarkers have been evaluated prospectively, one of these biomarkers, has been evaluated as host biomarker and urine test has been approved by the WHO [18], but they require validation in a larger cohort of samples. Our data showed that the comparison of the median baseline of 7 analytes, namely IL-1β, IL2, IL-8, IL-12p70, MCP-1, PDGF-BB, VEGF responses significantly differed between Mtb-infected and non TB groups.

Table 5. ROC curves features of the 11 markers increased in LTBI.

| ROC curve of non TB vs LTBI (Ag-Nil) | Area under the ROC curve | Std. Error | 95% confidence interval | Pvalue | cutoff | Sensitivity % | 95% CI | Specificity % | 95% CI | Likelihood ratio |
|--------------------------------------|--------------------------|------------|------------------------|--------|--------|---------------|--------|---------------|--------|----------------|
| IL-2                                 | 0.8968                   | 0.0453     | 0.8079 to 0.9856       | < 0.0001 | > 42.13 | 74.19         | 55.39% to 88.14% | 95    | 75.13% to 99.87% | 14.84 |
| IP10                                 | 0.7323                   | 0.07094    | 0.5932 to 0.8713       | 0.005487 | > 6226 | 67.74         | 48.63% to 83.32% | 85    | 62.11% to 96.79% | 4.516 |
| IFN-γ                                | 0.7323                   | 0.07094    | 0.5932 to 0.8713       | 0.005487 | > 64.24 | 64.52         | 45.37% to 80.77% | 90    | 68.30% to 98.77% | 6.452 |
| IL-13                                | 0.796                    | 0.06165    | 0.6751 to 0.9168       | 0.000403 | > 1.330 | 64.52         | 45.37% to 80.77% | 90    | 68.30% to 98.77% | 6.452 |
| MIG                                  | 0.8941                   | 0.06935    | 0.7582 to 1.030        | 0.000774 | > 6.547 | 88.24         | 63.56% to 98.54% | 90    | 55.50% to 99.75% | 8.824 |
| SCF                                  | 0.8765                   | 0.06837    | 0.7424 to 1.011        | 0.00132  | > 40.99 | 82.35         | 56.57% to 96.20% | 90    | 55.50% to 99.75% | 8.235 |
| b-NGF                                | 0.8156                   | 0.08294    | 0.6530 to 0.9782       | 0.007802 | > 0.5650 | 75           | 47.62% to 92.73% | 80    | 44.39% to 97.48% | 3.75  |
| IL-12-p40                            | 0.8                      | 0.09117    | 0.6213 to 0.9787       | 0.01048  | > 97.77 | 76.47         | 50.10% to 93.19% | 90    | 55.50% to 99.75% | 7.647 |
| TRAIL                                | 0.8471                   | 0.07543    | 0.6992 to 0.9949       | 0.003067 | > 37.66 | 70.59         | 44.04% to 89.69% | 90    | 55.50% to 99.75% | 7.059 |
| IL-2 Ra                              | 0.7778                   | 0.09485    | 0.5918 to 0.9637       | 0.02539  | > 22.65 | 60           | 32.29% to 83.66% | 88.89 | 51.75% to 99.72% | 5.4   |
| LIF                                  | 0.7647                   | 0.09289    | 0.5826 to 0.9468       | 0.0239   | > 28.31 | 64.71         | 38.33% to 85.79% | 90    | 55.50% to 99.75% | 6.471 |

https://doi.org/10.1371/journal.pone.0192664.t005
Several recent studies that have highlighted that various biomarkers explored in whole blood and peripheral blood mononuclear cells, investigated in adults or children, have been detected as alternative biomarkers for IFN-γ to detect Mtb-infected individuals [19–29]. In our study, cytokines, chemokines and growth factors showing a higher median concentration in active TB and LTBI compared to non TB, were not able to detect any differences between LTBI and active TB patients.

In contrast with our data, Anbarasu et al. have found an increase of PDGF in TB patients, compared with HD in response to M. tuberculosis culture filtrate proteins (CFPs), with other cytokines such as G-CSF, IL-1Ra, IL-6, IL-7, IL-8, IL-9 in endemic setting population, even if the study was limited to the low number of subjects analysed [29]. In fact, the increase of this cytokine probably is due to the different antigen used, very recently a distinct patterns of cytokines and chemokines has been demonstrated that are released in response to different innate ligands that interact with specific pattern recognition receptors[30].

The diagnostic accuracies of the different cytokines was evaluated by ROC curve analysis in order to discriminate the different study populations. We found that several cytokines were
able to discriminate, with a good performance, LTBI from non TB. From this analysis, 11 cytokines showed a good performance with the area under the curve $>0.8$. Similarly, from the analysis of the diagnostic accuracy of the markers evaluated between active TB patients and non TB patients, 13 markers were able to discriminate with an AUC $>0.78$, with two markers MIG and SCF, able to reach the best sensitivity and specificity of 90%.

The concept of combining multiple biomarkers to improve the potential to discriminate between LTBI and active TB has also been explored previously. Our data revealed that the six or seven-marker combinations correctly classified from 80% to 100% of non TB subjects, while could correctly identified from 77.78% to 88.89% of active TB patients and from 64–74% to 82,35% of LTBI subjects, highlighting that these combinations considerably improved the ability to discriminate between active TB and LTBI from non TB group, although the ability to predict non TB patients was found better reaching 90% of 100% of subjects who not have Mtb infection/disease.

Won et al. have investigated on the ability of eight Mtb antigen-specific biomarkers in the Mtb-infected group to be significantly different from those of the HCs, they have found that the combination of five Mtb-specific biomarkers and two unstimulated biomarkers, and one Mtb-specific biomarker ratio showed significant differences between active TB and LTBI. Three unstimulated biomarkers and 5 Mtb-specific biomarkers were significantly different between active TB and non TB groups [31]. Previous studies have reported that the

### Table 6. ROC curves features of the 14 markers increased in active TB.

| Biomarker | Area under the ROC curve | Std. Error | 95% confidence interval | p value | cutoff | Sensitivity% | 95% CI | Specificity% | 95% CI | Likelihood ratio |
|-----------|--------------------------|------------|------------------------|---------|-------|--------------|--------|--------------|--------|-----------------|
| IL2       | 0.7778                   | 0.09485    | 0.5918 to 0.9637       | 0.02539 | $>42.13$ | 81.48        | 61.92% to 93.70% | 95     | 75.13% to 99.87% | 16.3   |
| IP10      | 0.7942                   | 0.07397    | 0.6492 to 0.9393       | 0.000704 | $>6557$ | 80.77        | 60.65% to 93.45% | 85     | 62.11% to 96.79% | 5.385  |
| IFN-γ     | 0.8269                   | 0.06213    | 0.7051 to 0.9487       | 0.000148 | $>57.38$ | 70.37        | 49.82% to 86.25% | 90     | 68.30% to 98.77% | 7.037  |
| MIG       | 0.8944                   | 0.07156    | 0.7542 to 1.035        | 0.000669 | $>6.456$ | 94.44        | 72.71% to 99.86% | 90     | 55.50% to 99.75% | 9.444  |
| SCF       | 0.9353                   | 0.05365    | 0.8301 to 1.040        | 0.000205 | $>39.37$ | 94.12        | 71.31% to 99.85% | 90     | 55.50% to 99.75% | 9.412  |
| b-NGF     | 0.8765                   | 0.06869    | 0.7418 to 1.101        | 0.00132 | $>1.965$ | 70.59        | 44.04% to 89.69% | 90     | 55.50% to 99.75% | 7.059  |
| IL12-p40  | 0.8944                   | 0.06315    | 0.7706 to 1.018        | 0.000669 | $>86.37$ | 83.33        | 58.58% to 96.42% | 90     | 55.50% to 99.75% | 8.333  |
| TRAIL     | 0.9028                   | 0.06148    | 0.7823 to 1.023        | 0.000513 | $>34.01$ | 83.33        | 58.58% to 96.42% | 90     | 55.50% to 99.75% | 8.333  |
| IL2 Ra    | 0.8333                   | 0.08273    | 0.6711 to 0.9955       | 0.005499 | $>21.69$ | 55.56        | 30.76% to 78.47% | 88.89  | 51.75% to 99.72% | 5      |
| MIF       | 0.8706                   | 0.06827    | 0.7367 to 1.004        | 0.00157 | $<110.1$ | 76.47        | 50.10% to 93.19% | 90     | 55.50% to 99.75% | 7.647  |
| TNF-β     | 0.8667                   | 0.06776    | 0.7338 to 0.9995       | 0.001563 | $>5.405$ | 72.22        | 46.52% to 90.31% | 90     | 55.50% to 99.75% | 7.222  |
| IL3       | 0.8                      | 0.08311    | 0.6371 to 0.9629       | 0.009651 | $>155.0$ | 66.67        | 40.99% to 86.66% | 90     | 55.50% to 99.75% | 6.667  |
| IFN-α     | 0.8667                   | 0.0723     | 0.7249 to 1.008        | 0.001563 | $>13.35$ | 83.33        | 58.58% to 96.42% | 90     | 55.50% to 99.75% | 8.333  |
| LIF       | 0.7778                   | 0.08809    | 0.6051 to 0.9505       | 0.01655 | $>25.70$ | 66.67        | 40.99% to 86.66% | 90     | 55.50% to 99.75% | 6.667  |

https://doi.org/10.1371/journal.pone.0192664.t006
combination of three cytokines, TNF-α, with IL-1Ra or IL-10 correctly classified 95.5% or 100% of cases, respectively [21]. Furthermore, Frahm et al. also reported that the combination of MCP-1 and IL-15 correctly classified 86.4% of cases [28]. Collectively, these findings suggest that combining cytokine biomarkers results in more accurate discrimination between Mtb and non TB infection.

In a recent study, serum levels of eotaxin, MIP-1α, sIL-2Rα, and lipocalin 2 were found different expressed in pulmonary tuberculosis patients vs. non TB patients [32]. From these markers, eotaxin was found to be the most accurate immunological biomarker, as evaluated by ROC curve analysis, that differentiated pulmonary tuberculosis and non TB patients. The power to differentiate between the different cohorts was increased by evaluating 4 different biomarkers in combination (eotaxin, MIP-1α, sIL-2Rα, and lipocalin 2). This study did not
analyze these biomarkers as a biosignature of infection in LTBI subjects, limiting their use as diagnostic tools in discriminating between infection and disease.

In conclusion, our data add additional knowledge to the field of biomarkers that alone or in combination might further understanding of pulmonary tuberculosis infection/disease. A paucity of knowledge regarding specific biomarkers for pulmonary tuberculosis represents a big barrier to the development of diagnostic tests, specific treatment, and appropriate monitoring of disease. An additional large-scale study which target various Mtb-infected populations needs to be performed to validate the potential role of the different cytokines analyzed in detail in this study in order to validate their potential use as diagnostic biomarkers of Mtb infection.

Author Contributions

Conceptualization: Marco Pio La Manna, Valentina Orlando, Nadia Caccamo.

Data curation: Marco Pio La Manna, Valentina Orlando.

Software: Paolo Li Donni.

Supervision: Guido Sireci, Paola Di Carlo, Francesco Dieli, Nadia Caccamo.

Validation: Marco Pio La Manna, Valentina Orlando, Paolo Li Donni, Francesco Dieli.

Visualization: Paola Di Carlo, Antonio Cascio.

Writing – original draft: Francesco Dieli, Nadia Caccamo.

Writing – review & editing: Nadia Caccamo.

References

1. World Health Organization. Global tuberculosis report 2015. Geneva: WHO; 2015.

2. World Health Organization. The End TB strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. Available from: http://www.who.int/tb/post2015_TBstrategy.pdf?ua%20=1 (2015).

3. Uplekar M, Weil D, Lonroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new end TB strategy. Lancet. 2015 May 2; 385(9979):1799–1801. https://doi.org/10.1016/S0140-6736(15)60570-0 PMID: 25814376
1. Kik SV, Denkinger CM, Casenghi M, Vdnais C, Pai M. Tuberculosis diagnostics: which target product profiles should be prioritised? Eur Respir J. 2014; 44:537–40. https://doi.org/10.1183/09031936.00027714 PMID: 24696110

2. World Health Organization. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. Geneva: WHO; 2014. Available from: http://apps.who.int/bitstream/10665/135617/1/WHO-HTM-TB-2014.18_eng.pdf (accessed 19.9.16)

3. Stop TB Partnership. The Global Plan to Stop TB 2016–2020. Geneva: WHO; 2015. Available from: http://stoptbplan2020.org/wp-content/uploads/2015/06/Global-Plan-to-Stop-TB-2016-2020_Draft-9-June-2015_.pdf (accessed 19.9.16).256 S. Yerlikaya et al. / International Journal of Infectious Diseases 56 (2017) 253–257

4. World Health Organization. The End TB Strategy. Geneva: WHO; 2015. Available from: http://www.who.int/tb/strategy/End_TB_Strategy.pdf (accessed 19.9.16).

5. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, et al. An interferon- inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466(7309):973e7. https://doi.org/10.1038/nature09247 PMID: 20725040

6. Caccamo N, Guggino G, Joosten SA, Gelsomino G, Di Carlo P, Titone L, et al. Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol 2010; 40(8):2211 e20. https://doi.org/10.1002/eji.201040455 PMID: 20540114

7. Chegou NN, Black GF, Kidd M, van Helden PD, Walzl G. Hostmarkers in QuantiFERON supernatants differentiate active TB from latent TB infection: preliminary report. BMC Pulm Med 2009; 9:21. https://doi.org/10.1186/1471-2466-9-21 PMID: 19445695

8. Sutherland JS, de Jong BC, Jeffries DJ, Adetifa IM, Ota MO. Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort. PLoS One 2010; 5(8):e12365. https://doi.org/10.1371/journal.pone.0012365 PMID: 20811496

9. Mihret A, Bekele Y, Bobosha K, Kidd M, Aseffa A, Howe R, et al. Plasma cytokines and chemokines differentiate between active disease and non-active tuberculosis infection. J Infect. 2013 Apr; 66(4):357–65. https://doi.org/10.1016/j.jinf.2012.11.005 PMID: 23178506

10. Chegou NN, Essone PN, Loxton AG, Stanley K, Black GF, van der Spuy GD, et al. Potential of host markers produced by infection phase-dependent antigen-stimulated cells for the diagnosis of tuberculosis in a highly endemic area. PLoS One. 2012; 7(6):e38501. https://doi.org/10.1371/journal.pone.0038501 PMID: 22693640

11. Swet JA. Measuring the Accuracy of Diagnostic Systems. Science. 1988; 240(4857): 1285–1293. PMID: 3287615.

12. Yerlikaya S, Broger T, MacLean E, Pai M, Denkinger CM. A tuberculosis biomarker database: the key to novel TB diagnostics. Int J Infect Dis. 2017Mar; 56:253–257. https://doi.org/10.1016/j.ijid.2017.01.025 PMID: 28159577

13. Lawn SD, Kerkhof AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis. 2012 Mar; 12(3):201–9. https://doi.org/10.1016/S1473-3099(11)70251-1 PMID: 22015305

14. Ruhwald M, Bjerregaard-Andersen M, Rabna P, Eugen-Olsen J, Ravn P. IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay BMC Res Notes, 2 (2009), p. 19. https://doi.org/10.1186/1756-0500-2-19 PMID: 19193208

15. Tebruegge M, Dutta B, Donath S, Ritz N, Forbes B, Camacho-Badilla K, et al. Mycobacteria-specific cytokine responses detect tuberculosis infection and distinguish latent from active tuberculosis. Am J Respir Crit Care Med, 192 (4) (2015), pp. 485–499. https://doi.org/10.1164/rcrm.201501-0059OC PMID: 26030187

16. Hur YG, Kang YA, Jang SH, Hong JY, Kim A, Lee SA, et al. Adjunctive biomarkers for improving diagnosis of tuberculosis and monitoring therapeutic effects. J Infect, 70 (4) (2015), pp. 346–355. https://doi.org/10.1016/j.jinf.2014.09.019 PMID: 25452040

17. Armand M, Chhor V, de Lauzanne A, Guérin-E Khourouj V, Pédron B, Jeljeli M, et al. Cytokine responses to quantiferon peptides in pediatric tuberculosis: a pilot study. J Infect, 68 (1) (2014), pp. 62–70. https://doi.org/10.1016/j.jinf.2013.08.005 PMID: 23954615
23. Borgström E, Andersen P, Atterfelt F, Julander I, Källenius G, Mauerer M, et al. Immune responses to ESAT-6 and CFP-10 by FASCIA and multiplex technology for diagnosis of M. tuberculosis infection; IP-10 is a promising marker. PLoS One, 7 (11) (2012), p. e43438. https://doi.org/10.1371/journal.pone.0043438 PMID: 23144772

24. Kim SY, Park MS, Kim YS, Kim SK, Chang J, Lee HJ, et al. The responses of multiple cytokines following incubation of whole blood from TB patients, latently infected individuals and controls with the TB antigens ESAT-6, CFP-10 and TB7.7. Scand J Immunol, 76 (6) (2012), pp. 580–586. https://doi.org/10.1111/j.1365-3083.2012.02776.x PMID: 22946827

25. Wang X, Jiang J, Cao Z, Yang B, Zhang J, Cheng X, et al. Diagnostic performance of multiplex cytokine and chemokine assay for tuberculosis. Tuberculosis, 92 (6) (2012), pp. 513–520. https://doi.org/10.1016/j.tub.2012.06.005 PMID: 22824465

26. Skogstrand AH, Thyssen CS, Jorgensen EM, Rasmussen AB, Andersen T, Liliebaek T, et al. Antigen-induced cytokine and chemokine release test for tuberculosis infection using adsorption of stimulated whole blood on filter paper and multiplex analysis. Scand J Clin Lab Invest, 72 (3) (2012), pp. 204–211. https://doi.org/10.3109/00365513.2011.649014 PMID: 22283828

27. Kellar KL, Gehrke J, Weis SE, Mahmutovic-Mayhew A, Davila B, Zajdowicz MJ, et al. Multiple cytokines are released when blood from patients with tuberculosis is stimulated with Mycobacterium tuberculosis antigens. PLoS One, 6 (11) (2011), p. e26545. https://doi.org/10.1371/journal.pone.0026545 PMID: 22132075

28. Frahm M, Goswami ND, Owzar K, Hecker E, Mosher A, Cadogan E, et al. Discriminating between latent and active tuberculosis with multiple biomarker responses. Tuberculosis, 91 (3) (2011), pp. 250–256. https://doi.org/10.1016/j.tube.2011.02.006 PMID: 21393062

29. Anbarasu D, Raja CP, Raja A. Multiplex analysis of cytokines/chemokines as biomarkers that differentiate healthy contacts from tuberculosis patients in high endemic settings. Cytokine. 2013 Mar; 61 (3):747–54. https://doi.org/10.1016/j.cyt.2012.12.031 PMID: 23395366

30. Smith SG, Kleinnijenhuis J, Netea MG, Dockrell HM. Whole Blood Profiling of Bacillus Calmette-Guérin-Induced Trained Innate Immunity in Infants Identifies Epidermal Growth Factor, IL-6, Platelet-Derived Growth Factor-AB/BB, and Natural Killer Cell Activation. Front Immunol. 2017 Jun 6; 8:644. https://doi.org/10.3389/fimmu.2017.00644 PMID: 28634479

31. Won EJ, Choi JH, Cho YN, Jin HM, Kee HJ, Park YW, et al. Biomarkers for discrimination between latent tuberculosis infection and active tuberculosis disease. J Infect. 2017 Mar; 74(3):281–293. https://doi.org/10.1016/j.jinf.2016.11.010 PMID: 27871809

32. Choi R, Kim K, Kim MJ, Kim SY, Kwon OJ, Jeon K, et al. Serum inflammatory profiles in pulmonary tuberculosis and their association with treatment response. J Proteomics. 2016 Oct 21; 149:23–30. https://doi.org/10.1016/j.jprot.2016.06.016 PMID: 27321581